Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526004468?dgcid=rss_sd_all
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526004468?dgcid=rss_sd_all
“Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.” The Lancet Oncology.
@article{article68970,
title = {Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526004468?dgcid=rss_sd_all}
}